|
Eyeing COPD Market Boom, GSK, Theravance Plan Late 2012 Filing for Combo Drug
GlaxoSmithKline (GSK) and Theravance plan late 2012 regulatory filings for their new chronic obstructive pulmonary disease (COPD) candidate, saying initial Phase III data supports their plans to chip away at the $5 billion market share dominated by Boehringer Ingelheim’s Spiriva.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives